STAT3 and ovarian cancer: Pharmacologic inhibition of PARP1 with PARPi enhanced the tyrosine 705 (Y705) phosphorylation of STAT3 (p-STAT3) in ovarian cancer cell lines, which was mediated by dePARylation (17).